Otros idiomas Camurus AB

Acciones

Mercado cerrado - Nasdaq Stockholm Otros sitios de cotización 17:29:30 24/05/2024			Varia. Cinco días.	Varia. 1 de enero.
560,5 ^SEK	+1,82 %		-0,09 %	+4,18 %

23/05	Se acepta la revisión en la UE del fármaco de Camurus para el trastorno raro del crecimiento	MT
23/05	Camurus recibe la aceptación de la EMA de la solicitud de MAA para octreotida SC Depot (Cam2029) para el tratamiento de la acromegalia	CI

Camurus' Rare Growth Disorder Drug Accepted for Review in EU	23/05
Camurus receives EMA acceptance of MAA filing for octreotide SC depot (CAM2029) for the treatment of acromegaly	23/05
Camurus Receives EMA Acceptance of MAA Filing for Octreotide SC Depot for the Treatment of Acromegaly	23/05
Camurus : AGM minutes 2024	13/05
Resolutions at the annual general meeting 2024 in Camurus	08/05
Camurus' Interim Report January-March 2024	08/05
Camurus AB Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
Certain Shares of Camurus AB are subject to a Lock-Up Agreement Ending on 17-APR-2024.	17/04
Notice of annual general meeting 2024 in Camurus (publ)	02/04
Camurus AB Announces Board Resignations	02/04
Camurus Annual Report for 2023	28/03
Camurus' New Drug Application for Acromegaly Treatment Accepted by US FDA	05/03
Camurus announces FDA acceptance of NDA submission for Oclaiz™ for treatment of acromegaly	05/03
Camurus AB Announces FDA Acceptance of NDA Submission for Oclaiz? for Treatment of Acromegaly	05/03
AVIS D'ANALYSTES DU JOUR : Sanofi, Stellantis, Orange, STMicroelectronics, OVH, UCB, Valeo...	04/03
Camurus AB Reports Earnings Results for the Full Year Ended December 31, 2023	15/02
Nordic Shares Rose Thursday; Tomra Systems Climbed Highest	15/02
Camurus' Full Year Report 2023	15/02
Camurus AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	15/02
Camurus AB Provides Earnings Guidance for the Full Year 2024	15/02

No hay resultados para esta búsqueda